Share this article

Renaming to Mpox

NETEC is in the process of updating its web pages with the term “mpox” to reduce stigma and other issues associated with prior terminology. This change is aligned with the World Health Organization decision.

Dr. Corri Levine, NETEC expert and virologist at the University of Texas Medical Branch, shares three things you should know about mpox in kids.

Mpox Outbreak Extends to Pediatric Population

CDC Guidance for Pediatrics

See the CDC’s “Clinical Considerations for Monkeypox in Children and Adolescents” (CDC, https://www.cdc.gov/poxvirus/monkeypox/clinicians/pediatric.html, Accessed 8/23/2022) guidance for the latest information on the 2022 monkeypox outbreak.

Cases of Mpox in Children

To date, dozens of mpox cases have been reported in children globally, including a number of cases in the United States (CDC, https://www.cdc.gov/poxvirus/monkeypox/response/2022/demographics.html, Accessed 8/23/2022). Currently, the risk of mpox to children and adolescents remains low.

However mpox is spread through prolonged, physical contact and therefore household transmission is possible. Individuals should avoid direct skin-to-skin contact with someone suspected or confirmed of having mpox and avoid contact with clothing, bedding, or towels they may have used. See CDC guidance for cleaning and disinfecting shared spaces to reduce the risk of transmission (CDC, https://www.cdc.gov/poxvirus/monkeypox/specific-settings/home-disinfection.html, Accessed 8/23/2022).

Identifying Risks and Symptoms of Mpox in Children

Mpox rash can appear similar to other common childhood rashes. Pediatricians should consider mpox if a patient presents with a rash and generalized symptoms (CDC, https://www.cdc.gov/poxvirus/monkeypox/clinicians/clinical-recognition.html, 8/23/2022) and gather a thorough clinical history to identify any possible epidemiological risk factors.

While most cases in this outbreak have not led to severe disease, factors that increase this risk include immunocompromising conditions and a history of eczema or another skin condition. The risk for severe disease increases for children under 8 years of age. Learn more about the factors for high risk of severe disease from mpox (CDC, https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html, Accessed 8/23/2022).

Vaccines and Treatments for Kids

Two vaccines are available for children with a confirmed or suspected high-risk exposure. Learn more about the vaccines (CDC, https://www.cdc.gov/poxvirus/monkeypox/considerations-for-monkeypox-vaccination.html, Accessed 8/23/2022).

The first-line treatment for mpox, tecovirimat, is available via expanded access for an investigational new drug for use in children and adolescents. There is limited data on the use of these vaccines and treatments in children, and providers should discuss the risks and benefits with patients and caregivers. See the CDC’s guidance for using tecoviramat (CDC, https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html, Accessed 8/23/2022).

Mpox and Pediatrics: What Clinicians Need to Know

As the 2022 global mpox outbreak continues to spread in the U.S. and abroad, pediatricians should consider how mpox may affect their patients.

Ebola: NETEC has compiled clinical guidance, preparedness resources, and educational materials related to ebola to support healthcare professionals and healthcare teams seeking reliable, evidence-informed information.
Access the resource library here.

Close Welcome Bar